Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BEYONDSPRING INC.

(BYSI)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
0.6000 USD   +0.02%
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November 23, 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

BeyondSpring Inc. Announces Board Appointments

08/29/2022 | 08:45am EST

The Board of Directors of BeyondSpring Inc. appointed Dr. Jiangwen Majeti and Mr. Sihai Xu to the Board, effective immediately. Dr. Majeti is an investor, biotech company advisor, and an executive with more than twenty years of experience in the biotech and pharmaceutical industry. Most recently, she was the Head of Global Collaborations and General Manager, China of Erasca Inc. Prior to that, she was Global Category Leader for Roche External Alliance. She is the past president and currently serves on the board of directors of the Chinese-American Biopharmaceutical Society.

She is also a member of the BayHelix Group. Dr. Majeti earned her Ph.D. from the University of Wisconsin at Madison and obtained her postdoctoral training at the Howard Hughes Medical Institute of the University of California, San Francisco. She also earned an MBA from the Leavey School of Business at Santa Clara University, graduating as a member of the Beta Gamma Sigma Honor Society.

She completed her undergraduate studies in Biochemistry at Fudan University in China. Mr. Xu has been an accomplished financial executive for almost thirty years. Mr. Xu currently serves as the Chief Financial Officer and on the board of directors of BOJI Health Investment Management (Shanghai) Co.

Ltd., which he joined in 2014. Previously, he was the Chief Financial Officer of Henan Plastic Surgery Hospital, the Chief Financial Officer of Shanghai BOJI Hospital Investment Management Co. Ltd., and the Chief Financial Officer of Henan Zhiyi Investment Management Co.

Ltd. As financial advisor and strategic investor, Mr. Xu have participated in pre-IPO, IPO, and major asset restructuring for dozens of public companies in China and Hong Kong. Mr. Xu received his MBA from Renmin University of China and his Bachelor's Degree in Financial Accounting from Henan University of Economics and Law in China.


ę S&P Capital IQ 2022
All news about BEYONDSPRING INC.
11/25Sector Update: Health Care Stocks Flat To Higher Premarket Friday
MT
11/25BeyondSpring Receives Non-Compliance Notice From Nasdaq
MT
11/24BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements, November ..
AQ
11/23BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
AQ
09/19BeyondSpring Inc.(NasdaqCM:BYSI) dropped from S&P Global BMI ..
CI
09/13BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Mon..
AQ
09/13BeyondSpring Inc. Presents New Clinical Evidence of Plinabulin Protection of Granulocyt..
CI
08/31North American Morning Briefing: Stocks Look to -2-
DJ
08/29BeyondSpring Inc. Announces Board Appointments
CI
08/29BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease ..
AQ
More news
Analyst Recommendations on BEYONDSPRING INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -57,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,43x
Yield 2022 -
Capitalization 23,4 M 23,4 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 19,5x
Nbr of Employees 103
Free-Float 59,4%
Chart BEYONDSPRING INC.
Duration : Period :
BeyondSpring Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEYONDSPRING INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 1
Last Close Price 0,60 $
Average target price 2,30 $
Spread / Average Target 283%
EPS Revisions
Managers and Directors
Lan Huang Chairman & Chief Executive Officer
Elizabeth Adkins Czerepak Chief Financial Officer
Ramon W. Mohanlal Director, Chief Medical Officer, Executive VP-R&D
G. Kenneth Lloyd Chief Scientific Officer
Matthew Kirkby Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BEYONDSPRING INC.-86.76%23
VERTEX PHARMACEUTICALS44.05%80 935
REGENERON PHARMACEUTICALS, INC.17.41%79 191
BIONTECH SE-36.54%39 245
WUXI APPTEC CO., LTD.-34.05%30 708
GENMAB A/S22.93%29 471